PainChek Limited (ASX:PCK)
Australia · Delayed Price · Currency is AUD 0.2300
-0.0050 (-2.13%)
Feb 12, 2026, 3:36 PM AEST
PainChek Revenue
In the fiscal year ending June 30, 2025, PainChek had annual revenue of 3.36M AUD with 25.84% growth. PainChek had revenue of 1.70M in the half year ending June 30, 2025, with 44.64% growth.
Revenue
3.36M
Revenue Growth
+25.84%
P/S Ratio
14.92
Revenue / Employee
n/a
Employees
n/a
Market Cap
50.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.36M | 690.49K | 25.84% |
| Jun 30, 2024 | 2.67M | 716.07K | 36.61% |
| Jun 30, 2023 | 1.96M | 961.72K | 96.74% |
| Jun 30, 2022 | 994.15K | 760.26K | 325.05% |
| Jun 30, 2021 | 233.89K | -63.29K | -21.30% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mach7 Technologies | 33.79M |
| Beamtree Holdings | 28.60M |
| ImExHS | 26.32M |
| Resonance Health | 11.07M |
| PharmX Technologies | 7.53M |
| Vitasora Health | 3.71M |
| Emyria | 1.39M |
| TrivarX | 1.03M |
PainChek News
- 8 days ago - Painchek Ltd (ASX:PCK) (H1 2026) Earnings Call Highlights: Strategic US Expansion and Strong ... - GuruFocus
- 8 days ago - Half Year 2026 PainChek Ltd Earnings Call Transcript - GuruFocus